Skip to main content
. 2016 Feb 21;7(13):15959–15976. doi: 10.18632/oncotarget.7557

Figure 3. Treatment with AZD5363 reduces PTEN-deficient tumor progression.

Figure 3

Representative H&E stained sections of CNPC A., and CRPC C., from control and AZD5363 treated mice. Histopathological analysis of mPIN distribution in CNPC B., (n = 8 mice per group) and CRPC D., (n = 5 mice per group).